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Femorofemoral Bypass Graft
Y.W. Kim,1* J.-H. Lee,2 H.G. Kim2 and S. Huh2Divisions of Vascular Surgery, Departments of Surgery, 1Samsung Medical Center (SMC), Sungkyunkwan
University School of Medicine, Seoul, and 2Kyungpook National University Hospital (KNUH), Daegu,
South KoreaObjectives. To determine the factors affecting long-term patency of crossover femorofemoral bypass (FFB) graft.
Design. A retrospective clinical study of a prospectively registered database.
Materials. Two hundred and sixteen FFBs performed for 192 patients with atherosclerotic iliac occlusive disease.
Methods. The clinical and surgical variables influencing graft patency were assessed with log-rank test and Cox’s
proportional hazard analysis.
Results. The primary patency rates of all FFB grafts at 3 and 5 years were 73G4 and 65G5%, respectively. By multivariate
analysis, hypertension (Odds ratio 2.8, PZ0.002) and critical ischemia (Odds ratio 0.42, PZ0.01) significantly (P!.05)
influenced long-term patency of FFB grafts.
Conclusion. The long-term patency of FFB grafts was not affected by procedural modifications. Graft patency was inferior
in patients with severe lower limb ischemia but superior in patients with hypertension. Further study is required to clarify
the mechanism of an unexpected beneficial effect of hypertension on FFB graft patency.Keywords: Atherosclerosis; Iliac artery; Vascular graft occlusion; Risk factors.Introduction
Crossover femorofemoral bypass (FFB) has been used
for about 40 years as an extra-anatomic bypass for
patients with unilateral iliac artery occlusion. In the
early days after its introduction, FFB was reserved for
patients with unilateral iliac occlusion who were at
higher surgical risk for aortofemoral bypass (AFB).
Currently the majority of patients with iliac artery
stenosis are treated by endovascular intervention.
However, open surgical treatment is still rec-
ommended for a long iliac occlusion. Over the past
13 years, there have been changes in the indications for
FFBs and also procedural modifications. In this study,
we investigate how clinical and surgical factors affect
femorofemoral graft patency in a modern series of
patients.ng author. Young-Wook Kim, MD, FACS, Division of
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During a period of 13 years and 7 months from
January 1990 through August 2003, 230 FFB operations
were performed or supervised by one surgeon (YWK)
in a tertiary referral center of university hospital. Two
hundred and sixteen FFBs in 192 patients (male 91%,
mean ageGSD: 66G9 years) were included in this
study. Fourteen FFBs for non-atherosclerotic iliac
occlusions (trauma 5, Buerger’s disease 4, and unilat-
eral graft limb occlusion after AFB bypasses 5) were
excluded from the study. The demographic and
clinical features of the patients are demonstrated in
Table 1.Methods
Our indications for FFB were long segment unilateral
iliac disease corresponding to type C or D lesions
according to TASC classification1 and acute unilateral
iliac artery thrombosis when catheter-directed throm-
bolytic therapy was unavailable or contraindicated.
Selection of FFB over AFB was favoured for patients ofEur J Vasc Endovasc Surg 30, 376–380 (2005)
doi:10.1016/j.ejvs.2005.04.006, available online at http://www.sciencedirect.com onved.
Table 1. The demographic and clinical features of patients
Feature No (%)
Age (years), meanGSD (range) 66G9 (46–91)
Male (%) 196 (91)
Indications for FFB
Disabling claudication 105 (49)
Critical ischemia* 111 (51)
Coexisting morbidities
Hypertension† 111 (51)
Diabetes mellitus‡ 55 (25)
Ischemic heart disease§ 61 (28)
Cerebrovascular disease with
neurologic deficit
38 (18)
Moderate or severe COPD 34 (16)
Renal insufficiency (serum
creatininO2.0 mg/L)
17 (8)
SD, standard deviation; FFB, femorofemoral bypass; COPD, chronic
obstructive pulmonary disease.
* Critical ischemia denotes rest pain or ischemic tissue loss
regardless the mode of onset.
† Hypertension was defined as systolic blood pressureO
150 mmHg or diastolic blood pressureO95 mmHg on casual blood
pressure measurement or by history of patients taking antihyper-
tensive agents.
‡ Diabetes was defined as fasting blood sugarO125 mg/dL or by a
history of patients using hypoglycaemic agents or insulin.
§ Ischemic heart disease was defined as fixed or reversible
perfusion defect on myocardial perfusion scan or electrocardio-
graphic findings of myocardial infarction.
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ing morbidity, and according to patient’s preference.
When a thick, ulcerated or dissected intimal plaque
was found during FFB operation, femoral endarter-
ectomy was concomitantly performed in 31% of
patients. We used 7 or 8 mm diameter-sized e-
polytetrafluoroethylene (e-PTFE, Gore-Texw) grafts in
all patients according to the size of the femoral artery.
Among the patients showing recipient-side SFA
occlusion (nZ95 limbs, 44%), concomitant leg bypass
was performed in 63 patients (66%). Donor-side SFA
occlusion was not a contraindication for FFB grafting
in our institution.Table 2. Surgical variables of femorofemoral bypasses (FFBs)
FFB procedure (NZ216)
Urgent operation (!24 h after symptom onset)
Second operation with new graft
Donor-side iliac artery intervention
Preoperative PTA or stenting
Ilio-femoral prosthetic graft interposition
Concomitant recipient-side leg bypass
Femoral endarterectomy
Anastomosis at distal DFA‡
Diameter of e-PTFE graft
7 mm
8 mm
PTA, percutaneous transluminal angioplasty; e-PTFE, expanded-polyt
* Performed for 23 graft occlusions and one graft revealing tight sten
patients were transferred from other hospitals with graft occluded or r
† Two patients underwent concomitant ilio-femoral interposition due
‡ Distal DFA denotes segment of deep femoral artery distal to the laThe frequencies of surgical variables are demon-
strated in Table 2. Postoperatively, all patients were
prescribed 100–300 mg of oral aspirin daily. FFB graft
patency was assessed by duplex ultrasonography
every 3 months. Data were retrieved from the pre-
registered vascular database at KNUH. SPSS for
Windows (version 10.0; SPSS Inc., Chicago, Ill) was
employed for statistical analyses. Cumulative patency
rates were calculated with the Kaplan–Meier method.
To determine the factors influencing the long-term
patency of FFB graft, four clinical variables (hyperten-
sion, diabetes mellitus, critical ischemia, and recipient-
side SFA occlusion) and six surgical variables (urgent
operation, second FFB bypass, donor iliac artery
intervention, FFB graft diameter, femoral endarterect-
omy, and anastomosis at distal deep femoral artery
(DFA) were tested with univariate and multivariate
analysis. After univariate analysis with the log-rank
test, variables with P value!0.2 were applied into a
Cox’s proportional hazard model for multivariate
analysis. The Odds ratio and 95% confidence intervals
(95% CI) for the different variables were also esti-
mated. P!0.05 was considered significant.Results
After 216 FFB operations on 192 patients, one
operative death occurred in a patient with oxygen-
dependent, COPDwho required an emergency FFB for
limb-threatening acute iliac artery thrombosis. During
the follow-up period (mean 35G32 months; range 1–
170 months), we have observed 20 FFB graft failures
(9%) including two graft infections, 73 patients deaths
(38%), and 46 losses to follow-up (21%). Overall
primary cumulative patency rates of FFB grafts at 1,
3, and 5 years were 90G2, 73G4, and 65G5%,No (%)
37 (17)
24* (11)
34† (16)
25
11
73 (34)
67 (31)
24 (11)
103 (48)
113 (52)
etrafluoroethylene.
osis of both anastomotic sites. Among 23 graft occlusions, three
emoved due to graft infection.
to suboptimal results of preoperative iliac PTA.
teral circumflex branch.
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three variables including hypertension, critical ische-
mia and anastomosis at the distal DFA significantly
influenced the long-term patency of grafts (Table 3).
By multivariate analysis, hypertension and critical
ischemia significantly influenced the long-term
patency of FFB grafts (Table 4). While critical ischemia
adversely affected the FFB graft patency (Odds ratio
0.4; 95% CI, 0.2–0.8, PZ0.01), hypertension was a
protective factor (Odds ratio 2.8, 95% CI 1.5–5.5, PZ
0.002) (Table 4, Fig. 2).Discussion
Open surgical treatment is usually recommended for a
diffuse, long segment iliac occlusion while most iliac
artery stenoses are treated by endovascular interven-
tion. Though some authors2 reported an agressive
endovascular intervention for Type C lesions, the
Trans-Atlantic Intersociety Consensus (TASC)1 rec-
ommends surgical treatment for type C or D iliac
lesions. All candidates for FFBs in this study had type
C or D lesions according to TASC classification. We
performed FFB in patients older than 75-year-old
(18%), those with significant coexisting morbidities,
for those with acute iliac artery occlusion not suitable
for thrombolytic therapy (16%), or those requiring
concomitant leg bypass (34%). In deciding between
AFB and FFB, we also considered patients’
preferences.
During the period of this study, 96 AFBs and 31
axillobifemoral bypasses were performed for iliac
artery occlusive disease. Compared to AFB, the
lower patency rate of FFB was often attributed to theFig. 1. Primary cumulative patency of femorofemoral bypass
grafts (NZ216).
Fig. 2. Comparison of long-term cumulative patency of
femorofemoral bypass (FFB) grafts. (A) Blood pressure:
Hypertensive versus Normotensive. (B) Indications: Critical
ischemia versus Claudication. (C) Site of distal anastomosis:
Common femoral versus Distal deep femoral artery.
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Table 3. Univariate analysis of risk factors for femorofemoral bypass (FFB) grafts
Variables No (%) P value
HypertensionO150 mmHg 111 (51) .006
Diabetes mellitus 55 (25) .117
Critical ischemia* 111 (51) .003
Urgent operation (!24 h after symptom onset) 37 (17) .105
Second operation with new graft 24 (11) .892
Outflow SFA occlusion 33 (15) .099
7 mm e-PTFE graft 103 (48) .678
Donor iliac artery intervention 34 (16) .327
Femoral endarterectomy 67 (31) .763
Anastomosis at distal DFA‡ 24 (11) .002
Log-rank test.
* Critical ischemia denotes rest pain or ischemic tissue loss regardless the mode of onset.
† Outflow SFA occlusion indicates untreated outflow superficial femoral artery occlusion or graft occlusion after concomitant leg bypass
during follow-up period.
‡ Distal DFA denotes segment of deep femoral artery distal to the lateral circumflex branch.
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namic drawback of acute-angle flow direction, and the
superficially located graft prone to infection or com-
pression. The postoperative progression of donor-side
iliac lesionwas reported as a cause of FFB graft failure,3,4
but its frequency was not remarkable ranging from 1 to
6%.5–7 To obtain optimal results after crossover FFB, a
satisfactory donor iliac artery inflow source is a
prerequisite. Porter et al.8 first introduced donor-side
iliac intervention before FFB operation for a patientwith
donor-side iliac artery stenosis and good success has
been reported since that time.9–11 However, Aburahma
et al.12 reported that donor-side iliac angioplasty and
stenting for a long (O5 cm) segment stenosis failed
to support FFB grafting. Other authors reported that
FFB grafts failure resulted from the progression of
outflow arterial disease in the recipient limb.6,13–15
Criado et al.16 reported that there was no difference in
FFB graft patency rates between the patients with
critical limb ischemia and those with claudication.
However, they described that overall limb preser-
vation rate was poor in patients with limb-threatening
ischemia. The authors also noted that recipient-side
SFA occlusion did not affect the long-term patency of
FFB grafts. The effect of recipient-side SFA occlusion
on the patency of FFB grafts is controversial.17,18
Though our study has limitation due to itsTable 4. Multivariate analysis of risk factors for femorofemoral
bypass (FFB) grafts
Variables P value Odd’s ratio (95% CI)
HypertensionO150 mHg .002 2.840 (1.478–5.457)
Diabetes mellitus .164 1.883 (0.772–4.592)
Critical ischemia .010 0.418 (0.215–0.814)
Urgent operation (!24 h
after symptom onset)
.380 0.714 (0.337–1.515)
Outflow SFA occlusion .723 1.176 (0.480–2.881)
Anastomosis at distal
DFA
.060 0.423 (0.173–1.037)
Cox’s proportional hazard model.retrospective design with a high rate of losses to
follow-up, we observed statistically significantly
lower patency rate of FFBs in patients with critical
ischemia. But recipient-side SFA occlusion did not
affect FFB graft patency. According to other reports,
variables such as patients’ age, recipient-side femoral
occlusion, prior arterial surgery in the groin, surgery
for acute ischemia and concomitant distal arterial
revascularization were inconclusive risk factors for
FFB graft occulsion.18,19 An Italian group20 reported
that the only risk factor for the graft patency and limb
salvageafter FFBwasaprevioushistoryofvasculargraft
failure. Even though, we could not find any differences
ingraft patencybetweenprimaryand secondFFBgrafts,
we have experienced two graft infections after second
FFB operations but not following primary operations.
We used 7 or 8 mm diameter smooth-walled e-PTFE
graft in all patients. We found no significant difference
in graft patency between the two size grafts. Interest-
ingly, Mingoli et al.20 reported significantly better
primary and secondary patency rates of externally
supported grafts comparing to smooth wall PTFE
graft. Adjunctive procedures such as femoral endar-
terectomy or donor-side iliac intervention can expand
surgical indications for FFB without compromising
FFB graft patency. The site of the distal anastomosis of
the FFB or the requirement for femoral endarterect-
omy did not affect graft patency.
Hypertension is a well-known risk factor for the
development of atherosclerosis. But certain anti-
hypertensive medications are beneficial to vein graft
patency.21 To our knowledge, no previous reports
indicate that hypertension has a protective effect on
prosthetic graft patency.
In this study, we could not make a subgroup
analysis of hypertensive patients according to the
hypertensive agents. Therefore, we cannot conclude
whether the beneficial effects of hypertension on FFBEur J Vasc Endovasc Surg Vol 30, October 2005
Y. W. Kim et al.380graft patency was derived from anti-hypertensive
medication or not.
In summary, we report that FFB can be performed
in various types of iliac artery occlusion by modifying
its procedure. These procedural modifications can
broaden its indications without adversely effecting
graft patency. Among the various clinical and surgical
variables, critical ischemia and hypertension influ-
enced the long-term patency of FFB grafts. The
beneficial effect of hypertension on prosthetic graft
patency should be clarified by a prospective study.References
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